Streetwise Reports Features 3D Signatures
Test for Personalized Approach to Hodgkin's Lymphoma
Treatment Entering Final Stages Before Commercialization
Source: Streetwise Reports (1/16/18)
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company,
which is at the forefront of using three-dimensional telomere analysis to personalize
3D Signatures Inc. (DXD:TSX.V; TDSGF:OTCQB; 3D0:FSE) has developed a propriety software platform, TeloView, that conducts 3D analysis of chromosomal signatures. "Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity," the company has noted. The analytics can tell "doctors how to personalize treatment and best manage the disease for each individual patient."
The firm completed a Stage 3 clinical trial component for its Hodgkin's lymphoma test, Telo-HLTM, in October; the test is powered by their proprietary TeloViewTM software platform. The aim of the Telo- HLTM test is to divide patients at the point of diagnosis into those who will respond to standard chemotherapy and those who will not, and should be considered for a more targeted, and expensive, second-line therapy.
Currently, patients for whom the standard chemotherapy treatment fails then have to go on to a number of additional interventions and more aggressive alternative treatments. Patients with a relapsing form of the disease often are weakened by the initial chemo treatments so they do not respond as well to the subsequent treatment.
While about 80% of Hodgkin's patients respond to the standard chemotherapy regimen, 3D Signatures CEO Jason Flowerday told Streetwise Reports that the goal of the test is to identify the 20% of patients who will relapse and require additional therapies, to save them from treatments that are unlikely to succeed. In addition, the company believes that its Telo-HLTM test could "provide significant cost savings to payors and insurers that
are currently burdened with expensive treatments and procedures that may not be necessary if patients could be considered for more targeted and effective therapies at the outset of treatment."
3D Signatures is now having the Telo-HLTM data validated by a third-party statistical provider, as well as preparing for validation of the scoring model. If both validations are successful, the company plans to make the
test commercially available in the coming months. In addition to the Hodgkin's lymphoma test, 3D Signatures is developing diagnostic and prognostic products
for prostate cancer, multiple myeloma and lung cancer, all at various stages of development, and finally for Alzheimer's disease, a diagnostic test that has successfully completed two blinded research studies.
On Jan. 5, Daniel Carlson of Tailwinds Research Group noted that for 3D Signatures, "2017 was a year to forget. The stock went down dramatically on the back of a very poor financing effort. However, like the Phoenix, sometimes big disasters can turn into outstanding revivals. 3DS is poised to enter into several
partnerships for its interesting technology. Meanwhile, the stock's valuation discounts all success. I expect shares to advance in lockstep with the company's development of their telomere technology and for 2018 to mark a dramatic turnaround for the Company."
3D Signatures has approximately 63 million shares outstanding with about 27% controlled by insiders. The company's market cap is approximately CA$18 million.
Read more at http://www.stockhouse.com/companies/bullboard/v.dxd?postid=27376865#6fxIb8l3cQ0ZhOcq.99